文献速递安宁疗护多重用药

非技能型养老院入住时他汀停药与限制生命疾病的关系

Statin Discontinuation and Life-Limiting Illness in Non-Skilled Stay Nursing Homes at Admission.
PubMed 文献 · J Am Geriatr Soc · 2020-08-17

该回顾性队列纳入2015至2016年新入住美国非技能型养老院的73,247名65岁及以上Medicare按服务收费受益人,评估入住后30天内他汀停药情况。总体停药率为19.9%,且随限制生命疾病严重程度升高而增加,但多数居民无论疾病状态如何仍在继续使用他汀。

要点

  • 入住养老院30天内总体他汀停药率为19.9%。
  • 临床指定为临终状态者30天停药率为45.0%,风险比为1.59。
  • 多数Medicare受益人在入住养老院后仍继续使用他汀。

核心结论

  • 新入住非技能型养老院的Medicare受益人中,约五分之一在30天内停用他汀,停药风险随限制生命疾病严重程度增加,但多数人仍继续用药。

研究设计与样本

  • 回顾性队列研究,使用2015至2016年Minimum Data Set 3.0入住评估与Medicare行政数据链接。
  • 纳入13,092家美国Medicare和Medicaid认证养老院中新入住非技能型床位的65岁及以上Medicare按服务收费受益人,共73,247名入住时使用他汀者。

主要发现

  • 总体30天他汀停药率为19.9%。
  • 无限制生命疾病者停药率20.5%,严重疾病者18.6%,接受姑息治疗咨询者34.5%,临床指定为临终者45.0%。
  • 以无限制生命疾病为参照,30天停药风险随疾病严重程度升高:严重疾病aRR=1.06(95%CI=1.02-1.10)。
  • 姑息治疗指数诊断aRR=1.15(95%CI=1.10-1.21),姑息治疗咨询aRR=1.58(95%CI=1.43-1.74),临床指定临终aRR=1.59(95%CI=1.42-1.79)。

关键数值与推荐

  • 限制生命疾病分类采用循证标准识别进展性、终末期疾病或预后有限(<6个月)者。
  • 停药定义为养老院入住后30天内无新的Medicare Part D他汀处方索赔。

临床怎么用

  • 对入住养老院的老年人应评估他汀获益,尤其对终末期或接受姑息治疗者可考虑安全停药。
  • 需研究如何让居民与医护人员共同参与,安全有效地停用获益存疑的药物。

局限性

  • 原文摘要未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To estimate 30-day statin discontinuation among newly admitted nursing home residents overall and within categories of life-limiting illness. DESIGN: Retrospective cohort using Minimum Data Set 3.0 nursing home admission assessments from 2015 to 2016 merged to Medicare administrative data files. SETTING: U.S. Medicare- and Medicaid-certified nursing home facilities (n = 13,092). PARTICIPANTS: Medicare fee-for-service beneficiaries, aged 65 years and older, newly admitted to nursing homes for non-skilled nursing facility stays on statin pharmacotherapy at the time of admission (n = 73,247). MEASUREMENTS: Residents were categorized using evidence-based criteria to identify progressive, terminal conditions or limited prognoses (<6 months). Discontinuation was defined as the absence of a new Medicare Part D claim for statin pharmacotherapy in the 30 days following nursing home admission. RESULTS: Overall, 19.9% discontinued statins within 30 days of nursing home admission, with rates that varied by life-limiting illness classification (no life-limiting illness: 20.5%; serious illness: 18.6%; receipt of palliative care consult: 34.5%; clinician designated as end-of-life: 45.0%). Relative to those with no life-limiting illness, risk of 30-day statin discontinuation increased with life-limiting illness severity (serious illness: adjusted risk ratio (aRR) = 1.06; 95% confidence interval (CI) = 1.02-1.10; palliative care index diagnosis: aRR = 1.15; 95% CI = 1.10-1.21; palliative care consultation: aRR = 1.58; 95% CI = 1.43-1.74; clinician designated as end of life: aRR = 1.59; 95% CI = 1.42-1.79). Nevertheless, most remained on statins after entering the nursing home regardless of life-limiting illness status. CONCLUSION: Statin use continues in a large proportion of Medicare beneficiaries after admission to a nursing home. Additional deprescribing research, which identifies how to engage nursing home residents and healthcare providers in a process to safely and effectively discontinue medications with questionable benefits, is warranted.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Mack DS, Baek J, Tjia J, et al. Statin Discontinuation and Life-Limiting Illness in Non-Skilled Stay Nursing Homes at Admission. J Am Geriatr Soc. 2020. PMID: 33270223. doi:10.1111/jgs.16777

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。